Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Dicerna Pharmaceuticals, Inc. Novo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisition December 28, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Expiration of Hart-Scott-Rodino Act Waiting Period for Novo Nordisk Tender Offer to Acquire Dicerna December 25, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Novo Nordisk to Acquire Dicerna November 18, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Two Targets Meet Preclinical Proof of Principle Criteria in Neurodegeneration and Pain Under Global Research Collaboration and Licensing Agreement With Lilly November 12, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 November 12, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Third Quarter 2021 Financial Results and Provides a Business Update November 09, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Presents PHYOX™2 and Primary Hyperoxaluria Healthcare Utilization Data at American Society of Nephrology (ASN) Kidney Week 2021 November 04, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna to Report Third Quarter 2021 Financial Results on Nov. 9, 2021 November 02, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Results for PHYOX™4, Single-Dose Study of Nedosiran in Primary Hyperoxaluria Type 3 (PH3) October 19, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Data to Be Presented at American Society of Nephrology (ASN) Kidney Week 2021 October 15, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Poster Presentations at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021 in November October 14, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 01, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Initiates Phase 1 Clinical Trial of DCR-AUD, a Novel Investigational GalXC™ RNAi Therapeutic Candidate for the Treatment of Alcohol Use Disorder September 28, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces New Executive Leadership Appointments September 22, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna to Participate in 16th Annual Citi Biopharma Conference September 02, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Second Quarter 2021 Financial Results and Provides a Business Update August 09, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Reports Positive Top-Line Results From PHYOX™2 Pivotal Clinical Trial of Nedosiran for the Treatment of Primary Hyperoxaluria August 05, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna to Report Second Quarter 2021 Financial Results on Aug. 9, 2021 August 02, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces FDA Clearance of Investigational New Drug (IND) Application for DCR-AUD for the Treatment of Alcohol Use Disorder July 29, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease July 21, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 01, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease June 22, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Dosing Completion in Nedosiran PHYOX™4 Clinical Trial for Treatment of Primary Hyperoxaluria Type 3 June 16, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna to Participate in 42nd Annual Goldman Sachs Global Healthcare Conference June 03, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces FDA Acceptance of Lilly’s Investigational New Drug (IND) Application for LY3819469 May 27, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces Boehringer Ingelheim’s Acceptance of Candidate for Development Under RNAi Research Collaboration and License Agreement May 24, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna to Participate in Upcoming Investor Conferences May 12, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Announces First Quarter 2021 Financial Results and Provides a Business Update May 06, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna to Report First Quarter 2021 Financial Results on May 6, 2021 April 29, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Dicerna Sells OXLUMO™ (lumasiran) Royalty Interest to Royalty Pharma for Up to $240 Million April 08, 2021 From Dicerna Pharmaceuticals, Inc. Via Business Wire Tickers RPRX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.